tbuckley/cabot-search huggingface dataset:
Endophenotype Research in Psychiatry—The Grasshopper Grows Up
Authors: Joshua L. Roffman
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
Authors: H. Jean Khoury, Dong-Wook Kim, Andrey Zaritskey, Carlo Gambacorti-Passerini, Andreas Hochhaus, Juan Navarro, Aaron P. Rapoport, Pedro Enrique Dorlhiac-Llacer, Maria Zanichelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Hagop M. Kantarjian, Jorge E. Cortes
Journal: Blood (2010)
B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom’s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.
Authors: Daniel Ditzel Santos, Olivier Tournilhac, Lian Xu, Hatjiharrisi Evdoxia, Zachary Hunter, Andrew Branagan, Robert Manning, Kenneth C. Anderson, Iqbal Grewal, Steven P. Treon
Journal: Blood (2004)
Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?.
Authors: John Horan, Brent R. Logan, Manza-A. Agovi, Hillard M Lazarus, Andrea Bacigalupo, Karen Ballen, Rodrigo Martino, Mark B. Juckett, Hanna J. Khoury, Christopher Bredeson, Vikas Gupta, Franklin O. Smith, Gregory Hale, Matthew Carabasi, Philip L. McCarthy, J. Douglas Rizzo, Marcelo C. Pasquini
Journal: Blood (2009)
The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1 Stimulates Expression of NK Cell Related Transcription Factors, Thereby It Facilitates Generation of Highly Functional NK Cells in Vitro
Authors: Mieke WH Roeven, Jeanette Cany, Frans Maas, Arwa Kohela, Jansen Joop, Nicole MA Blijlevens, Nicolaas PM Schaap, Harry Dolstra
Journal: Blood (2014)
Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History?
Authors: Kaitlin Hendrix, Najla Alali, Eric Padron, David Sallman, Alan F. List, Jeffrey E. Lancet, Rami S. Komrokji
Journal: Blood (2016)
Acute Silent Cerebral Ischemia Occurs More Frequently Than Silent Cerebral Infarction In Children with Sickle Cell Anemia
Authors: Charles T. Quinn, Robert C. McKinstry, Michael M. Dowling, William S. Ball, Michael A. Kraut, James F. Casella, Nomazulu Dlamini, Rebecca N. Ichord, Lori C. Jordan, Fenella J. Kirkham, Michael J. Noetzel, E. Steve Roach, Deborah Hirtz, Michael R. DeBaun
Journal: Blood (2010)
Comparable Progression-Free and Overall Survival Following Transplantation of Single Cord Blood with HLA-Matched Related Donor in Adults with Non-Remission Myeloid Malignancies
Authors: Hisashi Yamamoto, Naoyuki Uchida, Mitsuhiro Yuasa, Kosei Kageyama, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2016)
Representativeness of a Heart Failure Trial by Race and Sex
Authors: Stephen J. Greene, Adam D. DeVore, Shubin Sheng, Gregg C. Fonarow, Javed Butler, Robert M. Califf, Adrian F. Hernandez, Roland A. Matsouaka, Ayman Samman Tahhan, Kevin L. Thomas, Muthiah Vaduganathan, Clyde W. Yancy, Eric D. Peterson, Christopher M. O’Connor, Robert J. Mentz
Journal: JACC Heart Failure (2019)
Discovery of the First Pathogenic Human EPO Mutation Provides Mechanistic Insight into Cytokine Signaling
Authors: Ah Ram Kim, Jacob C Ulirsch, Stephan Wilmes, Ekrem Unal, Ignacio Moraga, Musa Karakukcu, Daniel Yuan, Shideh Kazerounian, Namrata Gupta, Stacey B Gabriel, Eric S Lander, Turkan Patiroglu, Alper Ozcan, Mehmet Ozdemir, Christopher Garcia, Jacob Piehler, Hanna Gazda, Daryl Klein, Vijay G Sankaran
Journal: Blood (2016)
Variables Affecting Kinetics of Minimal Residual Disease Clearance in Children with Lymphoblastic Leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) Protocols ALL97, ALL97/99 and ALL2003.
Authors: Ajay J. Vora9, S. Richards, J. Hancock, C. Mitchell, O. B. Eden, S. Kinsey, I. Hann, J. S. Lilleyman, N. Goulden
Journal: Blood (2005)
An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,
Authors: Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, Catherine Thieblemont, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, Yukio Kobayashi, Kensei Tobinai
Journal: Blood (2011)
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Authors: Wayne L. Furman, Sara M. Federico, Mary Beth McCarville, Barry L. Shulkin, Andrew M. Davidoff, Matthew J. Krasin, Natasha Sahr, April Sykes, Jianrong Wu, Rachel C. Brennan, Michael William Bishop, Sara Helmig, Elizabeth Stewart, Fariba Navid, Brandon Triplett, Victor M. Santana, Armita Bahrami, Gwendolyn Anthony, Alice L. Yu, Jacquelyn Hank, Stephen D. Gillies, Paul M. Sondel, Wing H. Leung, Alberto S. Pappo
Journal: Clinical Cancer Research (2019)

Abstract Purpose: We sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children with newly diagnosed high-risk neuroblastoma. Patients and Methods: We conducted a prospective nonrandomized, single-arm, two-stage, phase II clinical trial. Six courses of induction chemotherapy were coadministered with hu14.18K322A and followed with granulocyte–macrophage colony-stimulating factor (GM-CSF) and low-dose IL2. Consolidation was performed with a busulfan/melphalan preparative regimen. An additional course of hu14.18K322A was administered with parent-derived natural killer cells, when available, during consolidation. Hu14.18K322A, GM-CSF, IL2, and isotretinoin were then administered. Secondary outcomes included reduced tumor volume and semiquantitative 123I-metaiodobenzylguanidine scoring [i.e., Curie scores (CS)] at the end of induction. Results: Forty-two patients received hu14.18K322A and induction chemotherapy. This regimen was well tolerated, with continuous-infusion narcotics adjusted to patient tolerance. Partial responses (PR) or better after the first two chemoimmunotherapy courses occurred in 32 patients [76.2%; 95% confidence interval (CI), 60.6–88.0]. This was accompanied by primary tumor volume reductions (median, –76%; range, –100% to 5%). Of 35 patients with stage IV disease who completed induction, 31 had end-of-induction CSs of 2 or less. No patients experienced progression during induction. Two-year event-free survival (EFS) was 85.7% (95% CI, 70.9–93.3). Conclusions: Adding hu14.18K322A to induction chemotherapy produced early PR or better in most patients, reduced tumor volumes, improved CSs at the end of induction, and yielded an encouraging 2-year EFS. These results, if validated in a larger study, may change the standard of care for children with high-risk neuroblastoma.
Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.
Authors: Umeer Ashraf, Myron S. Czuczman, Cory Marvis, John Gibbs, Francisco J Hernandez-Ilizaliturri
Journal: Blood (2009)
Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004
Authors: Aristoteles Giagounidis, Alan List, Eva Hellström-Lindberg, Mikkael A. Sekeres, Ghulam J. Mufti, Brigitte Schlegelberger, John Morrill, Chengqing Wu, Barry S. Skikne, Pierre Fenaux, Gudrun Göhring
Journal: Blood (2013)
Peripartum cardiomyopathy: basic mechanisms and hope for new therapies
Authors: Melanie Ricke-Hoch, Tobias J Pfeffer, Denise Hilfiker-Kleiner
Journal: Cardiovascular Research (2019)

Abstract Peripartum cardiomyopathy (PPCM) is a life-threatening cardiomyopathy characterized by acute or slow progression of left ventricular (LV) systolic dysfunction (LV ejection fraction of &amp;lt;45%) late in pregnancy, during delivery, or in the first postpartum months, in women with no other identifiable causes of heart failure. PPCM patients display variable phenotypes and risk factor profiles, pointing to involvement of multiple mechanisms in the pathogenesis of the disease. The higher risk for PPCM in women with African ancestry, the prevalence of gene variants associated with cardiomyopathies, and the high variability in onset and disease progression in PPCM patients also indicate multiple mechanisms at work. Experimental data have shown that different factors can induce and drive PPCM, including inflammation and immunity, pregnancy hormone impairment, catecholamine stress, defective cAMP-PKA, and G-protein-coupled-receptor signalling, and genetic variants. However, several of these mechanisms may merge into a common major pathway, which includes unbalanced oxidative stress and the cleavage of the nursing hormone prolactin (PRL) into an angiostatic, pro-apoptotic, and pro-inflammatory 16 kDa-PRL fragment, resulting in subsequent vascular damage and heart failure. Based on this common pathway, potential disease-specific biomarkers and therapies have emerged. Despite commonalities, the variation in aetiology and mechanisms poses challenges for the diagnosis, treatment, and management of the disease. This review summarizes current knowledge on the clinical presentation of PPCM in the context of recent experimental research. It discusses the challenge to develop disease-specific biomarkers in the context of rapid changing physiology in the peripartum phase, and outlines possible future treatment and management strategies for PPCM patients.
Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).
Authors: David C. Seldin, Martha Skinner, Betul Oran, Karen Quillen, Kathleen T. Finn, Vaishali Sanchorawala
Journal: Blood (2006)
Understanding Neutropenia: The 20 Year Experience of the Severe Chronic Neutropenia International Registry (SCNIR)
Authors: David C. Dale, Audrey Anna Bolyard, Cornelia Zeidler, Tracy M. Marrero, Laurence A. Boxer, Peter E. Newburger, Blanche P. Alter, PK Morrow, Mary Ann Bonilla, Yigal Dror, Frank Firkin, Sally Kinsey, John E. Levine, Daniel C. Link, Lee Reeves, Philip S. Rosenberg, Akiko Shimamura, Karl Welte
Journal: Blood (2014)
Mouse Versus Human Extrinsic Cues Dictate Transformation Potential In BCR-ABL/BMI1-Induced Leukemia In Humanized Xenograft Models
Authors: Pallavi Sontakke, Richard W.J. Groen, Jennifer Jaques, Huipin Yuan, Anton Martens, Edo Vellenga, Jan Jacob Schuringa
Journal: Blood (2013)
PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP)
Authors: James B. Bussel, John D. Grainger, Purificacion Garcia de Miguel, Jenny M. Despotovic, Franco Locatelli, Thirachit Chotsampancharoen, Elena K. Donyush, Julian Sevilla Navarro, Bunchoo Pongtanakul, Patcharee Komvilaisak, Darintr Sosothikul, Victor S. Blanchette, Guillermo I. Drelichman, Lakshmanan Krishnamurti, Nongnuch Sirachainan, Philip Connor, Michele David, Susanne Holzhauer, Vladimir Lebedev, Richard S. Lemons, Dagmar Pospisilova, Ugo Ramenghi, Koh B. Boayue, Dana C. Matthews, Lisa M. Marcello, Malini Iyengar, Geoffrey W. Chan, Karen D. Chagin, Dickens Theodore, Kalpana K. Bakshi, Christine K. Bailey
Journal: Blood (2014)
Correlations between BCR-ABL Ratio and Cytogenetic Response at Months 12 of the Randomized French SPIRIT Study on Behalf the Fi-LMC Group.
Authors: Claude Preudhomme, Catherine Roche-Lestienne, Antoine Crinquette, Christophe Roumier, Virginie Eclache, Joëlle Guilhot, Francois Guilhot, François-Xavier Mahon
Journal: Blood (2006)
Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions
Authors: Kayo Kondo, Jan A. Burger, Keating Micheal, Jamie Tran, Muharrem Muftuoglu, May Daher, Hila Shaim, Philip Thompson, Nobuhiko Imahashi, Abdullah Alsuliman, William Wierda, Enli Liu, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood (2015)
CDKN2 Gene Deletion Impair Prognosis in Adult Ph+ Acute Lymphoblastic Leukemia Even in Tyrosine Kinase Inhibitors Era
Authors: Na Xu, Yuling Li, Xuan Zhou, Hongqian Zhu, Lin Li, Qisi Lu, Rui Cao, Huan Li, Qifa Liu, Liu Xiaoli
Journal: Blood (2015)
Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
Authors: Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey V. Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Yin Yang, Dana A. Kennedy, Andrei R. Shustov
Journal: Blood (2012)
Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma
Authors: Jordan Gauthier, Leona Holmberg, David Wu, William I. Bensinger, Ajay K. Gopal, Oliver W. Press, David G Maloney, Damian J. Green, Brian G. Till, Denys Byelykh, Andrei R. Shustov
Journal: Blood (2015)
Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Authors: Pamela S. Becker, Bruno C. Medeiros, Anthony Selwyn Stein, Frederick R. Appelbaum, Bart L Scott, Colleen Delaney, Megan Othus, Paul C. Hendrie, Kelda M. Gardner, Stephen Petersdorf, John M. Pagel, Roland B. Walter, Cynthia Parks, Elihu H. Estey
Journal: Blood (2012)
Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry
Authors: Rena Buckstein, Richard A. Wells, Nancy Zhu, Thomas J. Nevill, Heather A Leitch, Karen W.L. Yee, Brian Leber, Mitchell Sabloff, Rajat Kumar, Michelle Geddes, April Shamy, Max Levitt, Martha Lenis, Alex Mamedov, Liying Zhang, Shabbir MH Alibhai
Journal: Blood (2014)
Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization
Authors: Craig W. Freyer, Alex Ganetsky, Colleen Timlin, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Selina Luger, Jacqueline Smith, Edward Stadtmauer, David L. Porter
Journal: Blood (2018)
Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period
Authors: Martha L Louzada, Alejandro Lazo-Langner, Marc Carrier, Vi Dao, Jerry Zhang, Marc A. Rodger, Michael J. Kovacs, Philip Wells
Journal: Blood (2010)
Activation of a Novel Palmitoyltransferase through a t(6;14) Translocation In T/Myeloid Biphenotypic Leukemia and Subsets of Acute Myeloid Leukemia.
Authors: Yi Ning, Lei Yu, Jocelyn Reader, Ching Chen, Xianfeng Frank Zhao, Jung Sook Ha, Charles Lee, Teresa York, Ivana Gojo, Maria R Baer
Journal: Blood (2010)
Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.
Authors: Corey Cutler, Shuli Li, Haesook T. Kim, Edwin Alyea, Vincent Ho, Stephanie J. Lee, David C. Fisher, Robert Schlossman, David Miklos, Stephen Sonis, Robert Soiffer, Joseph H. Antin
Journal: Blood (2004)
Unbiased Metabolic Profiling Uncovers a Crucial Role for the Microbial Metabolite Butyrate in Modulating GI Epithelial Cell Damage from Gvhd
Authors: Nathan Mathewson, Anna Mathew, Katherine Oravecz-Wilson, Julia Wu, Tomomi Toubai, Corinne Rossi, Yaping Sun, Subramaniam Pennathur, Pavan Reddy
Journal: Blood (2014)
Post-Transplant Positron Emission Tomography Using Fluorine 18-Fluoro-Deoxyglucose ([18F]FDG-PET) Correlates with Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma Undergoing High Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation (HDC/ASCT).
Authors: Adetola A. Kassim, Shin Mineishi, John P. Greer, Natalie McVay, Tatsuki Koyama, Wichai Chinratanalab, Stephen J. Brandt, Madan Jagasia, Katherine Ruffner, Friedrich G. Schuening, Richard S. Stein, Madhuri Vusirikala, Stacey Goodman, David S. Morgan
Journal: Blood (2004)
Mosaic variant in <i>ATP2C1</i> presenting as relapsing linear acantholytic dermatosis
Authors: J.A. Katzman, R. Chavan, A.C. Holliday, G. Coman, D. Grider, M.S. Kolodney
Journal: British Journal of Dermatology (2019)

Relapsing linear acantholytic dermatosis (RLAD) is a rare disease that manifests as recurring episodes of crusted and vesicular lesions distributed in a Blaschkoid pattern with histology resembling Hailey-Hailey disease. RLAD, in the presence of generalized disease, has been shown to be a type 2 mosaic form of Hailey-Hailey disease. RLAD, without systemic disease, has been hypothesized to be type 1 mosaic Hailey-Hailey disease, but this assertion has lacked genetic conformation. To determine the genetic abnormalities causing RLAD, we performed exome sequencing of affected tissue and blood in one patient. Exome sequencing of a punch biopsy revealed a c.238A>T, p.(Lys80*) variant in ATP2C1 found in 26% of the reads from lesional skin but absent in germline DNA. This somatic variant causes a truncated protein that would likely result in loss of function. Our findings indicate that, in this patient, RLAD is a clinical presentation of type 1 segmental Hailey-Hailey disease. What's already known about this topic? Relapsing linear acantholytic dermatosis (RLAD) is postulated to be a mosaic form of Hailey-Hailey disease. This hypothesis has remained unproven for type 1 disease and the putative gene and driving genetic variants have remained unknown. What does this study add? Exome sequencing, performed on lesional skin and matched blood, found RLAD lesions to be mosaic for variants causing a premature stop codon in ATP2C1. Our findings support the hypothesis that RLAD is a type 1 segmental form of Hailey-Hailey disease caused by postzygotic variants in ATP2C1.
Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.
Authors: Jana Jakubikova, Steffen Klippel, Efstathios Kastritis, John Daley, Melissa Ooi, Jake Delmore, Jacob P. Laubach, Paul G Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2010)
Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience
Authors: Adam Bryant, Elizabeth Pringle, Christopher Bredeson, David S. Allan, Grizel Anstee, Isabelle Bence-Bruckler, Linda Hamelin, Harry Spencer Hopkins, Lothar B. Huebsch, Mitchell Sabloff, Dawn C. Sheppard, Jason Tay, Harold Atkins
Journal: Blood (2014)
Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis
Authors: Sabrina Bossio, Laura De Stefano, Mariavaleria Pellicanò, Angela Palummo, Francesca Storino, Nadia Caruso, Giovanni Iaquinta, Giovanna Cutrona, Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Fortunato Morabito, Antonino Neri
Journal: Blood (2015)
Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients.
Authors: Maurizio Zangari, Federica Cavallo, Louis M. Fink, Bart Barlogie, Vanessa Bolejack, Michael J. Burns, Elias Anaissie, Klaus A. Hollmig, Abid Mohiuddin, Mauricio Pineda-Roman, Guido J. Tricot
Journal: Blood (2006)
Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial
Authors: Wolfram Pönisch, Simone Heyn, Ina Wagner, Martin Mohren, Franz-Albert Hoffmann, Frank Schüler, Marion Schmalfeld, Haifa K. Al-Ali, Nadja Jäkel, Dietger W Niederwieser
Journal: Blood (2010)
Bromodomain and Extra-Terminal Motif Proteins (BETs) Mediate 5-Azacitidine Resistance in Myeloid Leukemia through Recruitment of an Active RNA Polymerase II Complex
Authors: Li Chen, Yuan Li, Ming Yue, Adam Cloe, Michelle M. Le Beau, Chuan He, Richard A. Larson, James W. Vardiman, Jason X. Cheng
Journal: Blood (2016)
Elevated Plasma Levels and Platelet-Associated Expression of the Pro-Thrombotic and Pro-Inflammatory Protein, LIGHT (TNFSF14), In Sickle Cell Anemia (SCA)
Authors: Vanessa T. Garrido, Venina M. Dominical, Renata Proença-Ferreira, Marcos André Cavalcanti Bezerra, Mariana R. B. Mello, Aderson S Araujo, Sara T. Olalla-Saad, Fernando Ferreira Costa, Nicola Conran
Journal: Blood (2010)
The Abnormal Repression of Mir-375 Expression By Overlapping Epigenetic Dysregulations in Myelomas
Authors: Shotaro Tatekawa, Yoshiaki Chinen, Yuji Shimura, Yayoi Matsumura-Kimoto, Hisao Nagoshi, Tsutomu Kobayashi, Eri Kawata, Tomoko Narita, Masaki Ri, Hiroshi Handa, Nobuhiko Uoshima, Shinsuke Iida, Junya Kuroda
Journal: Blood (2016)
ABT-737 Targets Intrinsic Apoptosis during Cooperation of BCL-2 and Oncogenic NRAS in An in Vivo Progression Model of Myelodysplasia/Acute Myeloid Leukaemia
Authors: Nader Omidvar, Stephanie Beurlet, Carole Le Pogam, Anne Janin, Christophe Leboeuf, Annie Soulie, Niclas Setterblad, Maria-Elena Noguera, Laure Sarda-Mantel, Pascal Merlet, Marika Pla, Scott C. Kogan, Irving L Weissman, Marina Konopleva, William Bormann, Michael Andreeff, Christine Chomienne, Rose Ann Padua
Journal: Blood (2008)
A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma
Authors: Raija Silvennoinen, Pekka Anttila, Marjaana Säily, Tuija Lundan, Jouni Heiskanen, Timo Siitonen, Sakari Kakko, Mervi Putkonen, Hanna Ollikainen, Venla Terävä, Anu Partanen, Kirsi Launonen, Anu Räsänen, Anu Sikiö, Merja Suominen, Piotr Bazia, Kristiina Kananen, Tuomas Selander, Taru Kuittinen, Kimmo Porkka, Kari Remes, Esa Jantunen
Journal: Blood (2015)
Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes
Authors: Lorenzo Falchi, Long Xuan Trinh, Edith M. Marom, Mylene Truong, Ellen Schlette, Rachel L. Sargent, Xuemei Wang, Susan C. Smith, Susan Lerner, Michael J. Keating, Alessandra Ferrajoli
Journal: Blood (2012)
The Contribution of Toll-like Receptor (TLR) Pathway Hyper-Reactivity to Clonal Selection in Secondary MDS and AML
Authors: Laura F. Newell, R. K. Rathbun, Michael R Garbati, Kim-Hien T. Dao, Shernan G. Holtan, Rachel J Cook, Gabrielle Meyers, Grover C. Bagby
Journal: Blood (2014)
Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy
Authors: Sven Pannach, Julia Goetze, Luise Tittl, Thomas Schreier, Sandra Marten, Jochen Hampe, Jan Beyer-Westendorf
Journal: Blood (2016)